CL2015001168A1 - Compuestos derivados de 5-amino-1h-pirazol-4-carboxamida sustituidos, inhibidores de la tirosina-quinasa de bruton (bkt); composicion farmaceutica; metodo para inhibir la bkt; y metodo para tratar enfermedades autoinmunes, inflamatorias y cancer seleccionado de un trastorno proliferativo de celula b seleccionado de linfomas. - Google Patents

Compuestos derivados de 5-amino-1h-pirazol-4-carboxamida sustituidos, inhibidores de la tirosina-quinasa de bruton (bkt); composicion farmaceutica; metodo para inhibir la bkt; y metodo para tratar enfermedades autoinmunes, inflamatorias y cancer seleccionado de un trastorno proliferativo de celula b seleccionado de linfomas.

Info

Publication number
CL2015001168A1
CL2015001168A1 CL2015001168A CL2015001168A CL2015001168A1 CL 2015001168 A1 CL2015001168 A1 CL 2015001168A1 CL 2015001168 A CL2015001168 A CL 2015001168A CL 2015001168 A CL2015001168 A CL 2015001168A CL 2015001168 A1 CL2015001168 A1 CL 2015001168A1
Authority
CL
Chile
Prior art keywords
bkt
lymphomas
pyrazol
carboxamide
inflammatory
Prior art date
Application number
CL2015001168A
Other languages
English (en)
Spanish (es)
Inventor
John Robert Springer
Balekudru Devadas
Danny James Garland
Margaret Lanahan Grapperhaus
Seungil Han
Shaun Raj Selness
Daniel Patrick Walker
Zhao-Kui Wan
Li Xing
Susan Landis Hockerman
Robert Owen Hughes
Eddine Saiah
Mark Edward Schnute
Christoph Wolfgang Zapf
Michelle Ann Schmidt
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49596360&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015001168(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of CL2015001168A1 publication Critical patent/CL2015001168A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2015001168A 2012-11-02 2015-05-04 Compuestos derivados de 5-amino-1h-pirazol-4-carboxamida sustituidos, inhibidores de la tirosina-quinasa de bruton (bkt); composicion farmaceutica; metodo para inhibir la bkt; y metodo para tratar enfermedades autoinmunes, inflamatorias y cancer seleccionado de un trastorno proliferativo de celula b seleccionado de linfomas. CL2015001168A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261721920P 2012-11-02 2012-11-02
US201361772028P 2013-03-04 2013-03-04

Publications (1)

Publication Number Publication Date
CL2015001168A1 true CL2015001168A1 (es) 2015-07-10

Family

ID=49596360

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015001168A CL2015001168A1 (es) 2012-11-02 2015-05-04 Compuestos derivados de 5-amino-1h-pirazol-4-carboxamida sustituidos, inhibidores de la tirosina-quinasa de bruton (bkt); composicion farmaceutica; metodo para inhibir la bkt; y metodo para tratar enfermedades autoinmunes, inflamatorias y cancer seleccionado de un trastorno proliferativo de celula b seleccionado de linfomas.

Country Status (27)

Country Link
US (4) US20150291554A1 (enExample)
EP (1) EP2914586B1 (enExample)
JP (1) JP6178861B2 (enExample)
KR (1) KR101668574B1 (enExample)
CN (1) CN105008344B (enExample)
AP (1) AP2015008381A0 (enExample)
AU (1) AU2013340345B2 (enExample)
BR (1) BR112015009624A2 (enExample)
CA (1) CA2888960C (enExample)
CL (1) CL2015001168A1 (enExample)
CO (1) CO7350624A2 (enExample)
CR (1) CR20150228A (enExample)
DO (1) DOP2015000100A (enExample)
EA (1) EA201500393A1 (enExample)
ES (1) ES2625944T3 (enExample)
GE (1) GEP201606597B (enExample)
HK (1) HK1211293A1 (enExample)
IL (1) IL238571A0 (enExample)
MD (1) MD20150035A2 (enExample)
MX (1) MX2015005422A (enExample)
NI (1) NI201500059A (enExample)
PE (1) PE20151070A1 (enExample)
PH (1) PH12015500940A1 (enExample)
SG (1) SG11201502893WA (enExample)
TN (1) TN2015000168A1 (enExample)
TW (1) TWI518080B (enExample)
WO (1) WO2014068527A1 (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6348492B2 (ja) 2012-08-10 2018-06-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ブルトン型チロシンキナーゼ（ｂｔｋ）阻害剤としてのヘテロ芳香族化合物
AU2013312296B2 (en) 2012-09-10 2017-06-22 Principia Biopharma Inc. Pyrazolopyrimidine compounds as kinase inhibitors
CN103848810A (zh) * 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
US8895750B2 (en) 2013-03-14 2014-11-25 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as BTK inhibitors
US8940893B2 (en) 2013-03-15 2015-01-27 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as BTK inhibitors
KR102311329B1 (ko) * 2013-03-15 2021-10-14 얀센 파마슈티카 엔.브이. 약제를 제조하기 위한 방법 및 중간체
US9156847B2 (en) * 2013-03-15 2015-10-13 Janssen Pharmaceutica Nv Processes and intermediates for preparing a medicament
LT3035991T (lt) 2013-08-19 2020-11-10 Taris Biomedical Llc Daugiablokiai vaistų vartojimo įtaisai
CN104341388B (zh) 2013-10-16 2017-03-22 北京诺诚健华医药科技有限公司 芳香族酰胺类衍生物、其制备方法及其在医药上的应用
JP6486954B2 (ja) * 2014-01-29 2019-03-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｔｋ阻害剤としてのピラゾール化合物
KR20160117614A (ko) 2014-02-21 2016-10-10 프린시피아 바이오파마, 인코퍼레이티드 Btk 억제제의 염 및 고체 형태
WO2015185998A2 (en) * 2014-04-11 2015-12-10 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase
CN105085474B (zh) 2014-05-07 2018-05-18 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
GB201410430D0 (en) 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds
TW201607930A (zh) * 2014-07-18 2016-03-01 百濟神州有限公司 作為ｔ７９０ｍ／ｗｔ－ｅｇｆｒ的選擇性和不可逆的激酶抑制劑的５－氨基－４－氨甲醯基－吡唑化合物及其用途
WO2016019237A2 (en) * 2014-07-31 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
CN105884747B (zh) * 2014-08-28 2021-01-05 首药控股(北京)有限公司 一种制备布鲁顿酪氨酸激酶(btk)激酶抑制剂的制备方法
EA036269B1 (ru) 2014-12-18 2020-10-21 Принсипиа Биофарма Инк. Лечение пузырчатки
WO2016192074A1 (en) * 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Btk inhibitors
WO2016210165A1 (en) 2015-06-24 2016-12-29 Principia Biopharma Inc. Tyrosine kinase inhibitors
CN114685516A (zh) 2015-09-16 2022-07-01 洛克索肿瘤学股份有限公司 用于治疗癌症的作为btk抑制剂的吡唑并嘧啶衍生物
NZ741294A (en) * 2015-11-17 2023-07-28 Merck Patent Gmbh Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with btk inhibitory activity
CN108368086B (zh) 2015-12-16 2021-01-08 勃林格殷格翰国际有限公司 可用于治疗自身免疫疾病的二吡唑基衍生物
UA127863C2 (uk) * 2015-12-16 2024-01-31 Локсо Онколоджі, Інк. Сполуки, які можна застосовувати як інгібітори кінази
EP3402789B1 (en) 2016-01-13 2020-03-18 Boehringer Ingelheim International Gmbh Isoquinolones as btk inhibitors
CN107021963A (zh) 2016-01-29 2017-08-08 北京诺诚健华医药科技有限公司 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用
EP3433246B1 (en) 2016-03-24 2022-05-04 Mission Therapeutics Limited 1-cyano-pyrrolidine derivatives as dbu inhibitors
US10882843B2 (en) 2016-05-16 2021-01-05 Suzhou Sinovent Pharmaceuticals Co., Ltd. 5-aminopyrazole carboxamide derivative as BTK inhibitor and preparation method and pharmaceutical composition thereof
EP3478273A1 (en) 2016-06-29 2019-05-08 Principia Biopharma Inc. Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
GB201616511D0 (en) * 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) * 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
EP3548046A2 (en) 2016-12-03 2019-10-09 Juno Therapeutics, Inc. Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
WO2019071073A1 (en) 2017-10-06 2019-04-11 Forma Therapeutics, Inc. INHIBITION OF THE SPECIFIC PEPTIDASE OF UBIQUITIN
CN111212644B (zh) * 2017-11-10 2021-01-15 苏州信诺维医药科技有限公司 作为btk抑制剂的5-氨基吡唑甲酰胺化合物的无定型固体分散体
AU2018364183B2 (en) * 2017-11-10 2020-10-15 Sinomab Bioscience Limited Crystal form I of a 5-aminopyrazole carboxamide compound as BTK inhibitor
CN111225912B (zh) * 2017-11-10 2020-11-10 苏州信诺维医药科技有限公司 作为btk抑制剂的5-氨基吡唑甲酰胺化合物及其制备方法
ES2988920T3 (es) 2018-05-17 2024-11-22 Forma Therapeutics Inc Compuestos bicíclicos fusionados útiles como inhibidores de la peptidasa 30 específica de ubiquitina
CN108530436B (zh) * 2018-05-17 2020-12-29 黄传满 一种吡唑类化合物及其制备方法和应用
AU2019356011B2 (en) 2018-10-05 2025-02-06 Forma Therapeutics, Inc. Fused pyrrolines which act as Ubiquitin-Specific Protease 30 (USP30) inhibitors
MX2021010544A (es) * 2019-03-14 2021-10-01 Calico Life Sciences Llc Inhibidores de la proteina tirosina fosfatasa y metodos para usarlos.
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
KR20220011669A (ko) * 2019-05-21 2022-01-28 얀센 파마슈티카 엔.브이. Btk 억제제 제조를 위한 방법 및 중간체
EP4045051A1 (en) 2019-10-14 2022-08-24 Principia Biopharma Inc. Methods for treating immune thrombocytopenia by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
CA3159348A1 (en) 2019-11-08 2021-05-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
MX2022006631A (es) 2019-12-06 2022-09-07 Loxo Oncology Inc Dosificacion de un inhibidor de la tirosina cinasa de bruton.
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
PH12022551787A1 (en) 2020-01-22 2024-02-12 Principia Biopharma Inc Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
TWI809489B (zh) * 2020-09-10 2023-07-21 美商絡速藥業公司 用於製備(s)-5-胺基-3-(4-((5-氟-2-甲氧基苯甲醯胺基)甲基)苯基)-1-(1,1,1-三氟丙烷-2-基)-1h-吡唑-4-甲醯胺之方法及中間體
JP2023542503A (ja) * 2020-09-11 2023-10-10 カリコ ライフ サイエンシーズ エルエルシー タンパク質チロシンホスファターゼ阻害物質及びその使用方法
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
CN115611810B (zh) * 2021-07-16 2025-03-04 深圳市塔吉瑞生物医药有限公司 取代的吡唑类化合物及包含该化合物的组合物及其用途
CN116554102B (zh) * 2022-01-28 2025-10-03 深圳海博为药业有限公司 一种作为btk抑制剂的化合物及其制备方法和应用
AU2023216263A1 (en) * 2022-02-04 2024-08-22 Retune Pharma Inc. Certain chemical entities, compositions, and methods
WO2024153226A1 (zh) * 2023-01-19 2024-07-25 北京普祺医药科技股份有限公司 一种吡唑并环类化合物、药物组合物及其用途
WO2024153237A1 (zh) * 2023-01-19 2024-07-25 北京普祺医药科技股份有限公司 一种igf-1r酪氨酸激酶抑制剂、药物组合物及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
GB9608435D0 (en) * 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
WO2003072541A2 (en) * 2001-09-27 2003-09-04 Smithkline Beecham Corporation Chemical compounds
WO2007117692A2 (en) 2006-04-11 2007-10-18 Vertex Pharmaceuticals Incorporated Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases
EA018573B1 (ru) * 2006-09-22 2013-09-30 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
FR2908409B1 (fr) 2006-11-10 2009-01-09 Sanofi Aventis Sa Pyrazoles substituees,compositions les contenant,procede de fabrication et utilisation
WO2009011880A2 (en) * 2007-07-17 2009-01-22 Amgen Inc. Heterocyclic modulators of pkb
CN105362277A (zh) * 2008-07-16 2016-03-02 药品循环有限公司 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
AU2009273197B2 (en) 2008-07-24 2014-01-16 Nerviano Medical Sciences S.R.L. 3,4-diarylpyrazoles as protein kinase inhibitors
CA2771822C (en) 2009-09-04 2020-08-11 Daniel A. Erlanson Bruton's tyrosine kinase inhibitors
EP2582668B1 (en) 2010-06-16 2016-01-13 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
JP6348492B2 (ja) * 2012-08-10 2018-06-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ブルトン型チロシンキナーゼ（ｂｔｋ）阻害剤としてのヘテロ芳香族化合物
CN103848810A (zh) * 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
FR3002733B1 (fr) 2013-03-04 2015-08-14 Servier Lab Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2015157408A2 (en) 2014-04-09 2015-10-15 Donaldson Company, Inc. Self-supporting folded sheet material, filter elements, and methods
CN105085474B (zh) * 2014-05-07 2018-05-18 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂

Also Published As

Publication number Publication date
US20150291554A1 (en) 2015-10-15
CR20150228A (es) 2015-09-14
AU2013340345B2 (en) 2016-10-27
ES2625944T3 (es) 2017-07-21
CA2888960C (en) 2017-08-15
MX2015005422A (es) 2015-08-05
SG11201502893WA (en) 2015-05-28
MD20150035A2 (ro) 2015-10-31
DOP2015000100A (es) 2015-12-31
US10266513B2 (en) 2019-04-23
AU2013340345A1 (en) 2015-04-30
US20190202798A1 (en) 2019-07-04
TN2015000168A1 (fr) 2016-10-03
WO2014068527A1 (en) 2014-05-08
CN105008344B (zh) 2017-07-25
US20170283393A1 (en) 2017-10-05
PE20151070A1 (es) 2015-08-01
KR101668574B1 (ko) 2016-10-24
EP2914586A1 (en) 2015-09-09
CA2888960A1 (en) 2014-05-08
JP2015535277A (ja) 2015-12-10
CN105008344A (zh) 2015-10-28
EP2914586B1 (en) 2017-04-05
JP6178861B2 (ja) 2017-08-09
TWI518080B (zh) 2016-01-21
CO7350624A2 (es) 2015-08-10
TW201431851A (zh) 2014-08-16
PH12015500940A1 (en) 2015-06-29
US10815213B2 (en) 2020-10-27
HK1211293A1 (en) 2016-05-20
GEP201606597B (en) 2017-01-10
AP2015008381A0 (en) 2015-04-30
EA201500393A1 (ru) 2016-05-31
IL238571A0 (en) 2015-06-30
US20210002251A1 (en) 2021-01-07
BR112015009624A2 (pt) 2017-11-14
KR20150075114A (ko) 2015-07-02
NI201500059A (es) 2015-06-05

Similar Documents

Publication Publication Date Title
CL2015001168A1 (es) Compuestos derivados de 5-amino-1h-pirazol-4-carboxamida sustituidos, inhibidores de la tirosina-quinasa de bruton (bkt); composicion farmaceutica; metodo para inhibir la bkt; y metodo para tratar enfermedades autoinmunes, inflamatorias y cancer seleccionado de un trastorno proliferativo de celula b seleccionado de linfomas.
CL2015000094A1 (es) Compuestos derivados de imidazotriazincarbonitrilos, inhibidores de la proteina cinasa; composicion farmaceutica que los comprende; y su uso para tratar el cancer, psoriasis y artritis reumatoide.
BR112015002709A2 (pt) novos compostos de pirrolopirimidina como inibidores de proteínas quinases
CL2014003566A1 (es) Compuestos derivados de 7h-pirrolo[2,3-d]pirimidinas 4-(amimo-sustituidas), inhibidores de lrrk2; composicion farmaceutica que los comprende; y metodo para tratar la enfermedad de parkinson.
EP2721033A4 (en) COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS IDH1 MUTANT INHIBITORS FOR THE TREATMENT OF CANCER
CL2014003130A1 (es) Compuestos derivados de n-piridinil amidas ciclicas,inhibidores de quinasas pim; composicion farmaceutica que los comprende; combinacion farmaceutica; metodo para tratar enfermedades tales como canceres o un trastorno autoinmune.
SI3181567T1 (sl) Spojine pirazolopirimidina, kot inhibitorji kinaze
UY35249A (es) Inhibidores del receptor del factor de crecimiento de fibroblastos
BR112014000653A2 (pt) inibidores de tirosina quinase de bruton
CL2014002084A1 (es) Compuestos derivados microcíclicos, inhibidores de la quinasa del linfoma anaplásico; composicion farmaceutica; y un metodo para tratar la proliferacion celular anormal en un mamifero.
BR112013029620A2 (pt) inibidores de tirosina quinase de bruton
IL238728A0 (en) Pyrrolopyrimidine compounds as kinase inhibitors
DK2683384T3 (da) Fremgangsmåder til behandling af cancer under anvendelse af 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidin-2,6-dion
CL2015001160A1 (es) Compuestos derivados triciclicos fusionados de tiofeno, inhibidores de la cinasa janus (jak); composicion farmaceutica que los comprende; metodo para inhibir la actividad de jak1; metodo para tratar una enfermedad autoinmunitaria, un cancer, un trastorno mieloproliferativo y una enfermedad inflamatoria, entre otras enfermedades.
IL236495A0 (en) Heteroaromatic compounds as proton tyrosine kinase inhibitors
DK2818482T3 (da) Farmaceutisk sammensætning til behandling af cancer
EA201491579A1 (ru) Соединения оксазолидин-2-она и их применения в качестве ингибиторов pi3k
DK2824114T3 (da) Farmaceutisk sammensætning til behandling af cancer
CL2014003355A1 (es) Compuestos tricíclicos sustituidos, inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr); composicion farmaceutica que los comprende; metodo para tratar cancer, trastorno mieloproliferativo, trastorno esqueletico, trastorno de hipofosfatemia, entre otros.
EA201400412A1 (ru) ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
EA201391332A1 (ru) Лиганды опиоидных рецепторов и способы их применения и получения
MY177344A (en) Compounds and their methods of use
IN2014KN02906A (enExample)
DK2922828T3 (da) 4,6-diamino-pyrimidin-derivater som bmi-1-inhibitorer til at behandle cancer
EA201491013A1 (ru) Пиразиновые ингибиторы киназы